Taysha Gene Therapies, Inc. Common Stock
$5.06
$0.05 (+1.00%)
$4.90Day Range$5.19
Key Statistics
Market Cap
$1.65B
Shares Outstanding
325.8M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Sep 24, 2020
Round Lot
100
Locale
US
Trading Data
Day Open
$5.00
Day High
$5.19
Day Low
$4.90
Volume
5.15M
VWAP
$5.05
Prev Close
$5.01
Transactions
--
Acc. Volume
--
About Taysha Gene Therapies, Inc. Common Stock
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 283699 employees3000 PEGASUS PARK DRIVE, DALLAS, TX, 75247(214) 612-0000IPO Sep 24, 2020US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001806310
- Composite FIGI
- BBG00TJXFDP1
- Share Class FIGI
- BBG00TJXFDQ0
- Ticker Root
- TSHA
- SIC Code
- 2836
About Taysha Gene Therapies, Inc. Common Stock (TSHA) Stock
Taysha Gene Therapies, Inc. Common Stock (TSHA) closed the 2026-09-15 session at $5.06, up 1.00% versus the previous close (+0.05). The stock opened at $5.00 and traded between $4.90 and $5.19 during that session. Session trading volume was 5.1M shares. The volume-weighted average price (VWAP) is $5.05.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
Taysha Gene Therapies, Inc. Common Stock has a market capitalization of $1.65 billion. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. TSHA is listed on the XNAS exchange. The company employs approximately 99 people. Taysha Gene Therapies, Inc. Common Stock is headquartered in DALLAS, TX. The recorded listing date is 2020-09-24.
On this page you can find market TSHA stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.